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In this study, the potential effects of bacteria on the efficacy of frequently used chemotherapies
was examined. Bacteria and cancer cell lines were examined in vitro and in vivo for changes in
the efficacy of cancer cell killing mediated by chemotherapeutic agents. Of 30 drugs examined in
vitro, the efficacy of 10 was found to be significantly inhibited by certain bacteria, while the same
bacteria improved the efficacy of six others. HPLC and mass spectrometry analyses of sample drugs
(gemcitabine, fludarabine, cladribine, CB1954) demonstrated modification of drug chemical structure.
The chemoresistance or increased cytotoxicity observed in vitro with sample drugs (gemcitabine and
CB1954) was replicated in in vivo murine subcutaneous tumour models. These findings suggest that
bacterial presence in the body due to systemic or local infection may influence tumour responses or
off-target toxicity during chemotherapy.

Tumour responses to chemotherapy vary, and deeper insight into the reasons for therapeutic failure
with certain tumours while other apparently similar tumours respond well, stands to guide and improve
existing therapeutic regimes, while informing the development of new treatments. Bacteria have been
linked with various cancers in a number of ways1. For example, local bacterial-induced inflammation has
been linked with cancer promotion and progression, via indirect distal effects from the gastro intestinal
tract (GIT) microbiome, or directly such as in the case of Helicobacter pylori2,3. Recent research in experimental tumours has revealed that gut bacteria may influence the outcome of chemotherapy indirectly
via influencing the immune system4,5. For decades, naturally occurring bacteria of different types have
been isolated from patient tumours of various histological types1. In parallel to this, it is well known that
deliberate systemic administration of bacteria to animals or patients results in selective replication within
solid tumours6–9. Recently, we and others have characterised the bacterial populations naturally present
within malignant and non-malignant tissue of the breast10. We have reported the presence of a range of
bacteria in the breast tissue of cancer patients, while Xuan et al. reported similar findings in breast cancer
patients, and suggested differences in the types of bacteria present in malignant versus non-malignant
adjacent breast tissue10,11. Others have shown that bacteria such as E. coli and Fusobacterium are associated with colorectal cancer12–14.
Bacteria have the capacity to transform organic chemicals, such as nutrients, pollutants, toxins, drugs
and other organic molecules, via endogenous enzymes, and this is exemplified in the field of industrial
biotransformation in which various bacteria are used to chemically modify non-biological organic molecules15,16. Conceivably, there is potential for direct interaction between systemically administered drugs
at various body sites in the course of infection or in the case of orally administered drugs and microbiota of the small intestine. So far, the effects of in situ bacterial biotransformation of chemotherapeutics,
during cancer therapy have not been examined thoroughly. We sought to investigate if bacteria have the
potential to influence the efficacy of small drug chemotherapeutics.
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Results

In vitro assay design and validation. Various bacteria and cancer cell lines were examined in vitro

for changes in the efficacy of cancer cell killing mediated by a range of chemotherapeutic agents. An in
vitro assay was developed to facilitate drug and bacteria screening as described in experimental procedures and Fig. S1. Based on previously reported microbial analysis of tissue and tumour10,11 as well as our
own observations (Fig. S2) we chose to use E. coli as our main drug-testing agent, in addition to Listeria
welshimeri (see below). Assay validation proceeded with several drugs whose effects were observed to
be altered in the presence of E. coli. A drug whose efficacy was enhanced (Fig. 1a—AQ4N), and a drug
whose efficacy was decreased (Fig. 1b—gemcitabine) by E. coli were examined with a range of bacterial
concentrations. In both cases, a dose response (P <  0.01) was achieved using three different bacterial
concentrations, indicating that changes in drug cytotoxicity were originating from the bacteria. A dose
response using different drug concentrations (P <  0.01) was also demonstrated with the drug tegafur and
CB1954 (Fig. 1c,d).
In order to investigate if the observed effects were mediated by biochemical modification of the drugs,
rather than any physical bacterial drug absorption (e.g. in the case of gemcitabine), the in vitro assay
was performed with bacteria treated in a number of ways prior to incubation with drug. Gemcitabine
was examined with supernatant from E. coli which had been lysed by sonication. Similar decreases
in cytotoxicity were observed when gemcitabine was incubated with this lysate as with intact bacteria
(Fig. 1e,f). Upon heat-inactivation of the lysate (or intact bacteria), no reduction in cytotoxicity was
evident (P <  0.001), suggesting the involvement of enzymatic activity.

Effects of bacteria on chemotherapeutic drug cytotoxicity in vitro.

Studies proceeded with
bacterial strains representing frequently occurring bacterial species in patient tumours; Gram-negative
non-pathogenic E. coli and Gram-positive Listeria welshimeri (also non-pathogenic)10,11; Fig. S2.
Thirty agents from a number of different drug classes were examined, the majority of which represent
commonly-employed FDA-licenced drugs. The results are summarised in Table 1. Of 30 drugs examined, the cancer killing efficacies of 10 were found to be decreased, while in general the same bacteria
increased the efficacies of 6 others. 14 drugs did not display any difference in efficacy following bacteria
co-incubation. Observed effects on drug cytotoxicity were not identical between E. coli and L. welshimeri
(where tested), with E. coli increasing the effect of tegafur (unlike L. welshimeri), and decreasing the effect
of vidarabine, gemcitabine and etoposide phosphate (unlike L. welshimeri).

HPLC and mass spectrometry analyses. These findings prompted us to analyse a number of sample drugs to elucidate further the basis of drug alteration using HPLC and Mass Spectrometry. All of the
drugs tested produced new chromatogram peaks in the presence of bacteria indicating that they were all
biotransformed (Fig. 2). Further analysis of each peak by Mass Spectrometry revealed that gemcitabine
was biotransformed to a new mass of 306 m/z, (4.65 min) consistent with the formula C9H11N3O4F2 suggesting acetylation. Fludarabine and cladribine produced new masses of 154 m/z at 4.42 min (C5H5N5F)
and 170 m/z at 5.42 min (C5H5N5Cl35) respectively, consistent with an enzymatic hydrolysis of the nucleoside’s glycosidic bond yielding the halogenated purine bases. CB1954 (13.45 min) also produced a new
peak at 8.47 min in the presence of bacteria which upon further inspection resolved to two mass spectrometry peaks: 239 m/z and 223 m/z equivalent to the published hydroxylamine and amine derivatives
that are associated with a CB1954 reduction reaction17 (see Fig. 3 for the theoretical molecular structure
of the new derivatives).
Murine models of intratumoural bacterial effects on chemotherapy.

Our lab has previously
shown the ability of E. coli and other bacterial species to selectively replicate in tumours over time in
various murine models18,19. In this study, we initially validated the growth of E. coli in CT26 tumours
following intratumoural (i.t.) administration (Fig. S4). The chemoresistance observed in vitro (Fig. S3)
with a sample drug (gemicitabine) was examined in this model. Mice bearing CT26 tumours were i.t.
injected with E. coli or PBS, and intraperitoneally (i.p.) injected with gemcitabine or PBS and monitored over time (Fig. 4). As expected, the PBS:PBS and Bacteria:PBS groups showed the greatest tumour
volumes over time. Significantly increased tumour volume was observed in the gemcitabine +  bacteria
group compared with the gemcitabine alone group at various time points (P <  0.03; Fig. 4a). Survival was
significantly reduced in the gemcitabine +  bacteria group compared with the gemcitabine alone group
(17 days vs. 28 days + /− 1.25; P =  0.004; Fig. 4b). These data indicate reduced gemcitabine anti-tumour
activity in tumours containing bacteria. Bacteria alone did not significantly affect tumour volume relative
to PBS administration (P >  0.2), although some reduction is evident in bacteria administered tumours,
suggesting that the reduced gemcitabine effect may be partially masked.
The ability of the same bacterial species to activate the cytotoxicity of another drug, CB1954, was also
examined in this model. A significant increase in median survival (26 days vs. 8 days. P =  0.028) was
observed in the CB1954 +  bacteria group compared with the CB1954 alone group (Fig. 5), indicating
drug activation by the intratumoral bacteria.
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Figure 1. Tumour Cell Survival. Cell survival assay. (a) E.coli at different cfu/ml were co-incubated
with AQ4N (10 μ M) after which the supernatant was applied directly to LLC cells (P <  0.01). (b) E. coli
at different cfu/ml were co-incubated with gemcitabine (10 μ M) after which the supernatant was directly
applied to 4T1 Luc cells (P <  0.01). E.coli was co-incubated with Tegafur (c) or CB1954 (d) at the indicated
concentrations after which the supernatant was directly applied to TRAMPC1 cells or CT26 (P <  0.01). Data
(a–f) represent the average and standard error of four technical replicates. Data shown are representative
of 3 independent experiments. (e) Tumour cell survival assay stained with MTS. Gemcitabine (10 μ M) was
incubated with live or heat killed E. coli (P <  0.001). (f) Tumour cell survival assay. Gemcitabine (10 μ M)
was incubated with either bacterial lysate (equivalent amounts to cell survival assay live bacteria dosages)
alone or bacterial lysate that has been heat inactivated (P <  0.001). Data represent the average and standard
error of four technical replicates. Data shown are representative of 2 independent experiments.
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Cytotoxicity
Drug Name

Drug Class

E. coli

L. welshimeri

Tegafur

Anti-metabolite

Up

NC

Fludarabine de phosphate

Anti-metabolite

Up

Up

Capecitabine

Anti-metabolite

NC

NC

5-fluorocytosine

Anti-metabolite

Up

NC
NC

5-fluorouracil

Anti-metabolite

NC

6-Mercaptopurine-2′ -deoxyriboside

Anti-metabolite

Up

n/d

Pentostatin

Anti-metabolite

NC

NC
NC

Cytarabine

Anti-metabolite

NC

Clofarabine

Anti-metabolite

NC

NC

Cladribine

Anti-metabolite

Down

Down

Valacyclovir

Anti-metabolite

NC

n/d

Ara G hydrate

Anti-metabolite

NC

NC

Nelarabine

Anti-metabolite

NC

NC

Vidarabine

Anti-metabolite

Down

NC

Gemcitabine

Anti-metabolite

Down

NC

Doxorubicin

Anti-tumour Antibiotics

Down

n/d

Daunorubicin

Anti-tumour Antibiotics

Down

Down

Vinblastine

Anti-tumour Antibiotics

NC

n/d

Actinomycin

Anti-tumour Antibiotics

NC

n/d

Idarubicin

Anti-tumour Antibiotics

Down

n/d
n/d

Mitomycin C

Anti-tumour Antibiotics

NC

Streptonegrin

Anti-tumour Antibiotics

NC

n/d

Etoposide phosphate

Topo Isomerase Inhibitor

Down

NC
NC

Irinotecan

Topo Isomerase Inhibitor

NC

AQ4N

Topo Isomerase Inhibitor

Up

n/d

Mitoxantrone

Topo Isomerase Inhibitor

Down

n/d

Β -Lapachone

Topo Isomerase Inhibitor

Down

n/d

Estramustine

Alkylating Agent

NC

n/d

CB1954

Alkylating Agent

Up

Up

Menadione

Reactive oxygen generator

Down

n/d

Table 1. Summary of observations from in vitro cytotoxicity screen of drugs with bacteria using the
bacterial cell kill assay. n/d = not determined, NC = No Change.

Discussion

In this work we examined the ability of wild type bacterial species encountered in the body to influence
the efficacy of popular chemotherapeutic drugs that are administered to patients undergoing treatment
in the hope of broadening our understanding of bacteria-drug interactions. It is well known that the
human body has its own microbiome which differs from one individual to another, with the majority
of available information confined to ‘tract’-related body regions20,21, but also recently placenta, a unique
tissue type sharing many features with tumours22. Recent data presented by Xuan and co-workers11 and
our group10 describe a multitude of different bacteria taxa living naturally within breast tumours and in
the surrounding healthy tissue. The ability of bacteria to opportunistically proliferate or induce infections within tumours of cancer patients has been a sporadic diachronic phenomenon which dates as far
back as 200 years23. For example, in 1926 Glover stated that certain bacteria were consistently isolated
from neoplastic tissue24. Between the years 1936–1955 several publications reported that microbes were
present in cancer tissue1 (it was observations similar to those that ignited interest in using bacteria
as anticancer agents leading to the development of Bacillus Calmette-Guérin (BCG) as treatment for
bladder cancer25). Previous publications detailing sequence analyses of tissue from patients with breast
cancer demonstrated the presence of many species, of which proteobacteria dominated followed by fermicutes10,11. Furthermore, tissue colonisation as a consequence of cancer chemotherapy is known to occur
by antibiotic resistant bacteria26.
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Figure 2. HPLC analysis of drug biotransformations. Chromatograms: (a) Top; Vehicle alone (PBS DMSO
0.1%), Bottom; E. coli alone (b) Top; Gemcitabine, Bottom; Gemcitabine and E. coli. (c) Top; Fludarabine,
Bottom; Fludarabine and E. coli (d) Top; Cladribine, Bottom; E. coli and Fludarabine. (e) Top; CB1954,
Bottom; E. coli and CB1954 The drugs and their derivatives were detected by UV absorbance at 254 nm.

As we reproduced similar results to Xuan and co-workers11 (Fig. S2), we chose E. coli (a proteobacterium) and Listeria welshimeri (a fermicute) for our studies, because of practical reasons but also
because they represent a Gram-negative and a Gram-positive species respectively which have dissimilar
outer membranes and metabolism making them attractive for comparative drug studies. Most of the
current drug arsenal is composed of small molecular weight organic molecules which are subject to
biotransformation (enzymatic modification or degradation) by different tissue enzymes (e.g. cytochrome
P45027). However, biotransformations can also originate from bacteria which have their own unique
‘enzymolome’.
Scientific Reports | 5:14554 | DOI: 10.1038/srep14554
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C10H13N5O3Cl

C5H5N5Cl

286m/z

154m/z

H

C10H13N5O4F

253m/z

C5H5N5F

N

239m/z

NO2

N
NHOH

Bacterial Reduction

H2N

H2N
O

NO2
CB1954

C9H9N4O5

+
O

NO2

C9H11N4O4

223m/z N
NH2
H2N
O

NO2

C9H11N4O3

Figure 3. Schematic of drugs and proposed derivatives. Structure prediction of drugs and derivatives
based on mass spectrometry analysis. Hypothetical illustrations of structures based on elemental
composition analysis and atomic mass fitting of HPLC peaks of drugs or drug derivatives after co-incubation
with bacteria. For each molecule, its empirical formula and mass to charge ratio is also shown.

Initial assay tests were performed with E. coli and gemcitabine, AQ4N, tegafur and CB1954 (Fig. 1).
Dose responses were achieved with both bacteria and drug as shown in Fig. 1(a–d) and these results
validated our in vitro assay. While the levels of bacteria used in this assay were arbitrary, such bacterial
numbers are not unrealistic in clinical settings28. The cumulative data indicate that the effects observed
were direct consequences of enzymatic biotransformation. Analysis of gemcitabine suggested that bacterial enzyme(s) was responsible for rescuing cells from its toxic effects as both heat inactivated bacteria or
bacteria lysates failed to protect cancer cells in its presence (Fig. 1e,f). Notably, no significant tumour cell
death was observed in vitro following incubation with supernatant from live or lysed bacteria cells alone
suggesting that there is no cytotoxicity arising from any internal toxic metabolite of E. coli (Fig. 1e,f).
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Figure 4. E. coli decreases the efficacy of gemcitabine in vivo. Subcutaneous flank CT26 tumours
growing in Balb/c mice were injected i.t with bacteria or PBS vehicle alone. Gemcitabine (60 mg/kg) was
injected i.p. five times at three day intervals. (a) Tumour volume (%) relative to the first day of gemcitabine
injection (day 0) is shown. *P <  0.03, **P =  0.002 (Bonferroni post hoc test) for gemcitabine alone versus
gemcitabine +  bacteria. (b) Kaplan-Meier plots showing mouse survival over time. The median survival post
Day 0 of the gemcitabine +  bacteria group was significantly less than that of the gemcitabine alone group
(17 days vs. 28 days + /− 1.25; P =  0.008). Data are expressed as mean ±  SEM of 4 to 8 individual mice per
group.

We decided to screen a panel of drugs which are indicated for various cancers, that would be large
enough to cover multiple drug classes to get a better view of the drug modification landscape. However,
certain drugs although popular, were omitted from this screen. For example, drugs such as cyclophosphamide, ifosfamide, vinorelbine and vincristine would require a P450 enzyme for modification which is
absent in E. coli and Listeria welshimeri29,30; the latter also lack the enzyme Carboxypeptidase G2 which
is required to degrade pemetrexed31; taxanes were unlikely to be modified by our strains as they are
artificially produced in bacteria to begin with32; finally, drugs such as cisplatin which have an inorganic
structure were also omitted. The drug screening was performed in different cell lines where we tested
each drug and scored only cases in which we observed a difference between bacteria/drug alone or in
combination (Table 1).
The cytotoxicities of approximately 20% of the drugs tested were increased, 30% were decreased and
50% were unaffected. The cytotoxicities of cladribine, vidarabine and gemcitabine and other popular drugs
like etoposide phosphate and anti-cancer antibiotics like doxorubicin were decreased by bacteria. The
majority of drugs were not affected by the presence of bacteria in our assays, at least at the concentrations
examined. The finding that bacteria activated fludarabine and 6-mercaptopurine-2-deoxyadenosine was
not surprising. In viral vector-based gene therapy, the enzyme purine nucleoside phosphorylase (PNP)
has been used to activate fludarabine when expressed by cancer cells following viral vector delivery33.
However, the productive interaction of bacteria with a drug in the context of our thesis is a complicated
process which may involve both cytoplasmic enzymes and cell membrane transporters before and after
a drug’s biotransformation. It may be more relevant to consider a bacterial cell as a reservoir of disparate
enzymes or as a biotransformational monad. In agreement with our observations, Chen et al.34 showed
that Salmonella can activate the nucleoside 6-methylpurine-2-deoxyadenosine to 6-methylpurine, a cytotoxic agent, intriguingly, despite the fact that fludarabine, vidarabine and cladribine have very similar
Scientific Reports | 5:14554 | DOI: 10.1038/srep14554
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Figure 5. E. coli increases the cytotoxicity of CB1954. Subcutaneous flank CT26 tumours growing in
Balb/c mice were injected i.t with bacteria or PBS vehicle alone. CB1954 (20 mg/kg) was injected i.p. for the
duration of the experiment at 3 day intervals. (a) Tumour volume (%) relative to the first day of CB1954
injection (day 0) is shown. (b) Kaplan-Meier plots showing mouse survival over time. The median survival
post Day 0 of the CB1954 +  bacteria group was significantly greater than that of the CB1954 alone group (26
days vs. 8 days. P =  0.0374). Data are expressed as mean ±  SEM of 3-5 individual mice per group.

structures, incubation with bacteria produced opposing effects on cytotoxicity. Similarly, we observed
opposite effects with AQ4N (banoxantrone) and its analogue mitoxantrone (Table 1). Consistent with
this, Westman et al.35 also reported that doxorubicin can be biotransformed by Streptomyces cell extracts
via deglycosylation by NADH dehydrogenase.
In order to gain a molecular insight, we analysed the products of gemcitabine and E. coli by HPLC and
mass spectrometry and discovered that a new extra peak appeared in the chromatogram which eluted
later than gemcitabine (Fig. 2). This new peak had a molecular ion of 306 m/z which indicated that biotransformation had indeed taken place, consistent with a theoretical acetylation at the nitrogen atom of
the amine group on the molecule’s base (Fig. 3). However, further molecular analysis would be required
to confirm this. The hydrolysis of fludarabine/cladribine to their purine base was not as surprising to
witness. Such a reaction is known to be mediated by the isolated enzyme PNP in various gene therapy
settings36. However, to our knowledge, a productive, direct interaction of live E. coli/ Listeria welshimeri
with these nucleosides in the context presented in this study (live cell biotransformation and influence of
efficacy) has not been reported to date. Especially interesting was the fact that bacteria could hydrolyse
cladribine to its chlorinated purine base, but in contrast to fludarabine, they rendered it ineffective (this
is also interesting as cladribine is now in clinical trials as an oral drug for multiple sclerosis37) The precise
molecular mechanism for this difference is currently unknown, but it is relevant to draw attention to
the fact that all the therapeutic nucleosides become activated intracellular38 so it may be that an extracellular activation of cladribine by E. coli along with residual free enzymes from dead bacteria, disables
its therapeutic potential. The reduction of CB1954 to its two canonical derivatives shown in Fig. 3 was
not a surprise and although this nitroreduction reaction is known to occur, the ability of Gram-positive
and negative genetically unmodified bacteria to turn over the prodrug and mediate cell killing has not
been shown before. From our screen it becomes apparent that bacteria have the capacity to influence
the therapeutic effects of both drugs (e.g. gemcitabine) or prodrugs (e.g. cladribine). The biochemical
events which follow after drug activation leading to cell death or drug deactivation are beyond the scope
of this project.
We replicated our in vitro observations in an experimental mouse model where we demonstrated
that bacteria can hamper the effects of a selected drug, focussing on the drug gemcitabine because of its
popularity as an anticancer agent and due to our interesting counterintuitive finding that bacteria can
neutralise its toxicity. We acknowledge that such a model is quite artificial compared with clinical reality
but it provides proof of principle. Nonetheless, it was apparent from the murine data that a growing in
vivo tumour supports bacterial growth and provides the environment to permit the effects on a sample
Scientific Reports | 5:14554 | DOI: 10.1038/srep14554
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drug as per the in vitro assay (Fig. 4). We further recapitulated the in vitro cytotoxicity data from an
activating drug (CB1954) in this in vivo model (Fig. 5). The in vitro (Fig. 1) and in vivo data with both
drugs examined (in which E. coli has opposing effects) are consistent.
Research in this context has primarily focused on the ability of gut microorganisms to affect the
metabolism of pharmaceutical agents (reviewed in39,40). One of the most popular cases studied has been
the anti-cancer agent irinotecan and its toxic GIT side effects41. The gut bacterium Eggerthella lenta
deactivates the cardiac drug digoxin influencing its concentration in body fluids40. Our findings take the
field of microbial-drug interaction a step further, away from the GIT. We have shown that the types of
bacteria found in tumours may influence tumour responses to certain chemotherapeutic drugs, either
positively or negatively, depending on the characteristics of the infection (different bacteria produced
different effects e.g. E. coli affected more drugs than Listeria). Notionally, drugs can encounter bacteria
at different parts of the body (i.e. an infectious focus) in different settings resulting in in situ biotransformation. Although bacterial infections do not occur frequently, they are by far not clinically irrelevant:
for example, infections of the skin are common42 and could induce local skin toxicity if they came in
contact with a drug that can be activated to a more toxic form, infections of the stomach by H. pylori
are common43 and can result in the breakdown of L-DOPA (used to treat Parkinson’s disease) affecting
its bioavailability44; monomicrobial or polymicrobial infections of tissues can arise from blood or solid
tumours44; bacteraemia due to solid tumours can also present itself in cancer patients45 and infections of
pleural effusions are not uncommon in thoracic disease of neoplastic origin46. Chemotherapy itself has
also been associated with increased bacterial infection47.
Our findings are also pertinent to alternative anti-cancer strategies that are emerging which investigate combinations of chemotherapy and bacteria to treat solid tumours. Specifically, our work could
interest groups working with the clinically approved anti-cancer bacterium BCG which is used to treat
bladder cancer25. Chemotherapy is used post BCG treatments48 or in combination with BCG49. In addition to this, early experimental systems that investigate the use of chemotherapy in conjunction with
bacteria (Gram-positive or Gram-negative strains)50,51 should also be aware of potential biochemical drug
interactions with their agent’s enzymolome.
In conclusion, our data bring attention to the fact that internal bacteria can interact with a drug therapy and could under certain circumstances influence treatment efficacy and/or side effects.

Conclusions

Our results show that live wild type bacteria with natural enzyme levels can affect the efficacy of some
anticancer agents either positively or negatively in vitro and in vivo, most likely via enzymatic modifications. Our findings indicate the potential for local or systemic bacterial infections to act as an in situ
biotransforming reservoirs which may complicate cancer therapy, through reducing anti-tumour efficacy
or increasing off-target toxicity. For drugs whose cytotoxicity is increased by bacteria, our data also support the potential to improve therapeutic index through deliberate modification of the bacterial content
of cancer patients or tumours.

Materials and Methods

Bacteria and cell lines. E. coli Nissle 1917 (UCC culture collection) was cultivated aerobically in

L-Broth or L-Agar (Sigma) at 37 °C. Bioluminescent E. coli was described by us previously18 and cultured
in the presence of 300 mg/ml erythromycin. Listeria welshimeri Serovar 6B SLCC5334 was purchased
from ECACC and cultivated at 37 °C in Brain Heart Infusion (BHI) medium. The E. coli nitroreductase
triple deletion mutant and its parent strain were kindly provided by Dr Antonio Valle52. Lewis Lung
Carcinoma (LLC), 4T1 (mouse mammary carcinoma) and CT26 (mouse colorectal carcinoma) cells were
purchased from ATCC and were propagated according to the supplier’s instructions. The murine recycled
prostate cancer cell line TRAMPC1 was kindly provided by Ciavarra RP53 of Eastern Virginia Medical
School, Norfolk USA, and propagated as described in54.

Drugs. All drugs and enzymes were purchased from Sigma except: Etoposide Phosphate (Santa Cruz),

Capecitabine (Santa Cruz), AQ4N (R&D), Nelarabine (A&B), and Vidarabine (Santa Cruz). Drugs were
resuspended in H2O or DMSO, with appropriate control vehicle utilised accordingly in all experiments.

Cell cytotoxicity assay.

Microtitre plates (96-well) were pre-seeded with 4000 cells/well in appropriate medium for each cell line and allowed to attach overnight. On the day of the assay, bacteria were
cultured to log-phase and a subculture ratio, corresponding to an OD600nm of 0.2 determined for each
strain, was exposed for 2 h (4 h in the case of IC50s) to drug in falcon tubes containing DMEM in a tissue
culture incubator. Falcon content was filter-sterilized to remove presence of bacteria (using 0.2 μ m pore
filters (Starsted) before adding 200 μ l per well. Plates were incubated until cells in control (untreated)
had achieved confluent growth. Cytotoxicity was quantified using an MTS staining with the Cell Titre
96 AQueous One solution Cell Proliferation Assay (Promega). The plates were incubated with normal
media (80 μ l) and MTS solution (20 μ l) in a 37 °C incubator for approximately 2 h (until distinct change
of colour occurred).
Scientific Reports | 5:14554 | DOI: 10.1038/srep14554
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Bacterial lysis and heat inactivation. Bacteria were heat inactivated at 95 °C for 40 min. Lysis was

facilitated by sonication using three 10 sec pulses (at 20 Kz, 50 W). Between each pulse, samples were
incubated on ice for 30 seconds. A 20-fold drop in optical density was considered sufficient lysis.

HPLC and Mass spectrometry analyses. Sample preparation. Bacteria were grown to an OD600
between 0.8 and 1 in appropriate media. The bacteria were washed once in PBS and then resuspended in
the same volume of PBS. The drugs Fludarabine, Cladribine and Gemcitabine were dissolved in DMSO
(100 mM) and were added to the bacterial sample to give a final concentration of Fludarabine 10 μ M,
Cladribine 10 μ M and Gemcitabine 1 mM. Bacteria and drug were incubated for 1 h at 37 °C, and centrifuged at 13,500 rpm for 5 min. Supernatant containing drug was transferred to a spin filtration column
with a MWCO of 3000 (Vivaspin) and further centrifuged for 10 min at 13500 rpm. Samples were kept
on ice before HPLC analysis.
HPLC and Mass spectrometry analysis. The results described were obtained using a Waters Micromass
LCT Premier mass spectrometer (Instrument number KD160). Analysis was performed in ESI +  mode
using a gradient elution method to identify unknowns in the sample. An external reference standard of
Leucine enkephalin was infused in order to confirm mass accuracy of the Mass Spectrometre (MS) data
acquired. The samples were run in triplicate to ensure consistency and data were analysed by Masslynx
4.1 software. HPLC conditions: A waters Alliance 2695 with a 2996 Photodiode Array detector and
Waters Xbridge C18 5 μ m 150 ×  4.6 mm was used for the chromatographic separation with mobile phase:
Acetonitrile (containing 0.1% formic acid) and Water (containing 0.1% formic acid) using the following
gradient: 0 min (10:90); 0.5 min (10:90); 5 min (90:10); 10 min (100:0); 11 min (100:0); 11.1 min (10:90);
14 min (10:90). A flow rate of 0.5 ml/min, sample run time of 14 min and injection volume of 1–30 μ l
was used. For CB1954 the following gradient was used: 0 min (10:90); 0.5 min (10:90); 26 min (30:70);
27 min (10:90); 30 min (10:90). A flow rate of 1 ml/min, sample run time of 30 min and injection volume
of 10 μ l was used. The MS conditions were as follows: the samples were subjected to ESI +  ionisation
and acquired from 90 to 1250 m/z at a capillary voltage of 3.00 kV, sample cone of 30 V and a source
temperature of 140 °C. An external Enkephalin in Water/Acetonitrile (ESI +  m/z =  556.2771) for exact
mass correction using Lockspray was used. The UV conditions were set at a sampling rate of 1 spectrum/
second, scanning wavelengths from 195–400 nm at a resolution of 1.2 nm.
Murine experiments. All animal procedures were performed according to the national ethical guidelines
of the Health Products Regulatory Authority (HPRA). Protocols were approved by the University College
Cork Animal Experimentation Ethics Committee (AERR #2010/003 and #2012/015).
Animals and Tumour Induction. Mice were kept at a constant room temperature (22 °C) with a natural
day/night light cycle in a conventional animal colony. Standard laboratory food and water were provided
ad libitum. Before experiments, the mice were afforded an adaptation period of at least 7 days. Female
mice in good condition, without fungal or other infections, weighing 16–22 g and of 6–8 weeks of age,
were included in experiments (Harlan, Oxfordshire, UK). At experiment end, animals were euthanised
by cervical dislocation. For CT26 tumour induction, 6 ×  105 cells suspended in 200 μ l of serum-free
culture medium were injected subcutaneously (s.c.) into the flank. The viability of cells used for inoculation was greater than 95% as determined by visual count using a haemocytometer and Trypan Blue
Dye Exclusion (Gibco), or the Nucleocounter system (ChemoMetec, Bioimages Ltd, Cavan, Ireland).
Following tumour establishment, tumours were allowed to grow and develop and were monitored three
times weekly. Tumour volume was calculated according to the formula V =  (ab2) Π /6, where a is the
longest diameter of the tumour and b is the longest diameter perpendicular to diameter a. When tumours
reached approximately 100 mm3 in volume, mice were randomly divided into experimental groups.
Bacterial and drug administration. Overnight cultures of E. coli were re-inoculated into fresh LB (1/50
dilution) and incubated shaking at 37 oC until they reached an OD600 of 0.7. Cells were then washed
twice in PBS. Tumours were administered 106 E. coli in an injection volume of 50 μ l by intratumoral
(i.t.) injection. The viable count of each inoculum was determined by retrospective plating onto LB agar.
Two h post bacterial administration, drug (gemcitabine 60 mg/kg or CB1954 20 mg/kg) was administered
by intra-peritoneal (i.p.) injection in an injection volume of 50 μ l. The drug was subsequently administered on days 3, 6, 9, and 11 and animals not receiving drug were administered an equal volume of PBS
vehicle. For imaging experiments, mice were anesthetized via inhalation of isoflurane (Piramal Critical
Care, Inc).

Statistical analysis. For bioinformatics, statistical analysis was performed in R. For biological in vitro
and in vivo assays, two-sided, paired student’s t test with 95% confidence or Mann Whitney U test were
employed to investigate statistical differences, using GraphPad Prism or Microsoft Excel 12. Multiple
comparison tests were carried out using the Bonferroni post hoc test. Statistical significance of survival
between groups in murine experiments was determined using the Log-rank (Mantel-Cox) Test. Survival
curves are presented as Kaplan-Meier plots.
Scientific Reports | 5:14554 | DOI: 10.1038/srep14554

10

www.nature.com/scientificreports/

References

1. Cummins, J. & Tangney, M. Bacteria and tumours: causative agents or opportunistic inhabitants? Infectious agents and cancer 8,
11, doi: 10.1186/1750-9378-8-11 (2013).
2. Zambirinis, C. P., Pushalkar, S., Saxena, D. & Miller, G. Pancreatic cancer, inflammation, and microbiome. Cancer journal 20,
195–202, doi: 10.1097/PPO.0000000000000045 (2014).
3. Cummins, J., Cronin, M., van Pijkeren, J. P., Gahan, C. G. & Tangney, M. Bacterial systems for gene delivery to systemic tumors.
Methods in molecular biology 1141, 201–209, doi: 10.1007/978-1-4939-0363-4_13 (2014).
4. Viaud, S. et al. Gut microbiome and anticancer immune response. Cell death and differentiation, doi: 10.1038/cdd.2014.56 (2014).
5. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976,
doi: 10.1126/science.1240537 (2013).
6. Tangney, M. & Gahan, C. G. Listeria monocytogenes as a vector for anti-cancer therapies. Current gene therapy 10, 46–55 (2010).
7. Morrissey, D., O’Sullivan, G. C. & Tangney, M. Tumour targeting with systemically administered bacteria. Current gene therapy
10, 3–14 (2010).
8. Roberts, N. J. et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Science translational
medicine 6, 249ra111, doi: 10.1126/scitranslmed.3008982 (2014).
9. Bettegowda, C. et al. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nature biotechnology 24,
1573–1580, doi: 10.1038/nbt1256 (2006).
10. Urbaniak, C. et al. Microbiota of human breast tissue. Applied and environmental microbiology 80, 3007–3014, doi: 10.1128/
AEM.00242-14 (2014).
11. Xuan, C. et al. Microbial dysbiosis is associated with human breast cancer. PloS one 9, e83744, doi: 10.1371/journal.pone.0083744
(2014).
12. Bonnet, M. et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clinical cancer research: an official journal
of the American Association for Cancer Research 20, 859–867, doi: 10.1158/1078-0432.CCR-13-1343 (2014).
13. Flanagan, L. et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and
disease outcome. European journal of clinical microbiology & infectious diseases: official publication of the European Society of
Clinical Microbiology 33, 1381–1390, doi: 10.1007/s10096-014-2081-3 (2014).
14. McCoy, A. N. et al. Fusobacterium is associated with colorectal adenomas. PloS one 8, e53653, doi: 10.1371/journal.pone.0053653
(2013).
15. Arora, P. K. & Jain, R. K. Biotransformation of 4-chloro-2-nitrophenol into 5-chloro-2-methylbenzoxazole by a marine Bacillus
sp. strain MW-1. Biodegradation 23, 325–331, doi: 10.1007/s10532-011-9512-y (2012).
16. Nassar, A. F. in Biotransformation and Metabolite Elucidation of Xenobiotics 163–216 (John Wiley & Sons, Inc., 2010).
17. Helsby, N. A., Ferry, D. M., Patterson, A. V., Pullen, S. M. & Wilson, W. R. 2-Amino metabolites are key mediators of CB 1954
and SN 23862 bystander effects in nitroreductase GDEPT. British journal of cancer 90, 1084–1092, doi: 10.1038/sj.bjc.6601612
(2004).
18. Cronin, M. et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PloS one 7, e30940,
doi: 10.1371/journal.pone.0030940 (2012).
19. Cronin, M. et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Molecular therapy: the
journal of the American Society of Gene Therapy 18, 1397–1407, doi: 10.1038/mt.2010.59 (2010).
20. Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214,
doi: 10.1038/nature11234 (2012).
21. Haiser, H. J. & Turnbaugh, P. J. Is it time for a metagenomic basis of therapeutics? Science 336, 1253–1255, doi: 10.1126/
science.1224396 (2012).
22. Aagaard, K. et al. The placenta harbors a unique microbiome. Science translational medicine 6, 237ra265, doi: 10.1126/
scitranslmed.3008599 (2014).
23. Coley, W. Late results of the treatment of inoperable sarcoma by the mixed toxins of Erysipelas and Bacillus prodigosus. Am J
Med Sci 131, 375–430 (1906).
24. Glover, T. Progress in Cancer Research. Canada Lancet and Practitioner 67, 161–216 (1926).
25. Patschan, O. et al. Use of bacillus Calmette-Guerin in stage T1 bladder cancer: Long-term observation of a population-based
cohort. Scandinavian journal of urology 49, 127–132, doi: 10.3109/21681805.2014.968868 (2015).
26. Nguyen, A., Heil, E., Patel, N., Duffy, A. & Gilmore, S. A single-center evaluation of the risk for colonization or bacteremia with
piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis.
Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners,
doi: 10.1177/1078155214567161 (2015).
27. Kaspera, R. et al. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochemical pharmacology,
doi: 10.1016/j.bcp.2014.06.020 (2014).
28. Konig, C., Simmen, H. P. & Blaser, J. Bacterial concentrations in pus and infected peritoneal fluid–implications for bactericidal
activity of antibiotics. J Antimicrob Chemother 42, 227–232 (1998).
29. Kelly, S. L., Lamb, D. C., Jackson, C. J., Warrilow, A. G. & Kelly, D. E. The biodiversity of microbial cytochromes P450. Adv Microb
Physiol 47, 131–186 (2003).
30. Vredenburg, G. et al. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Toxicology letters 232, 182–192, doi: 10.1016/j.toxlet.2014.11.005 (2014).
31. Minton, N. P., Atkinson, T. & Sherwood, R. F. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its
expression in Escherichia coli and Pseudomonas putida. J Bacteriol 156, 1222–1227 (1983).
32. Boghigian, B. A., Salas, D., Ajikumar, P. K., Stephanopoulos, G. & Pfeifer, B. A. Analysis of heterologous taxadiene production
in K- and B-derived Escherichia coli. Applied microbiology and biotechnology 93, 1651–1661, doi: 10.1007/s00253-011-3528-4
(2012).
33. Sorscher, E. J., Hong, J. S., Allan, P. W., Waud, W. R. & Parker, W. B. In vivo antitumor activity of intratumoral fludarabine
phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer chemotherapy and pharmacology 70,
321–329, doi: 10.1007/s00280-012-1908-9 (2012).
34. Chen, G. et al. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination
therapy in murine melanoma model. Applied microbiology and biotechnology 97, 4393–4401, doi: 10.1007/s00253-012-4321-8
(2013).
35. Westman, E. L. et al. Bacterial inactivation of the anticancer drug doxorubicin. Chemistry & biology 19, 1255–1264, doi: 10.1016/j.
chembiol.2012.08.011 (2012).
36. Tai, C. K. et al. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with
the Escherichia coli purine nucleoside phosphorylase gene. Cancer gene therapy 17, 614–623, doi: 10.1038/cgt.2010.17 (2010).
37. Leist, T. P. et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first
demyelinating event (ORACLE MS): a phase 3 randomised trial. The Lancet. Neurology 13, 257–267, doi: 10.1016/S14744422(14)70005-5 (2014).

Scientific Reports | 5:14554 | DOI: 10.1038/srep14554

11

www.nature.com/scientificreports/
38. Robak, P. & Robak, T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer treatment reviews 39,
851–861, doi: 10.1016/j.ctrv.2013.03.006 (2013).
39. Sousa, T. et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. International journal of pharmaceutics
363, 1–25, doi: 10.1016/j.ijpharm.2008.07.009 (2008).
40. Haiser, H. J. & Turnbaugh, P. J. Developing a metagenomic view of xenobiotic metabolism. Pharmacological research: the official
journal of the Italian Pharmacological Society 69, 21–31, doi: 10.1016/j.phrs.2012.07.009 (2013).
41. Alimonti, A. et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer treatment reviews 30,
555–562, doi: 10.1016/j.ctrv.2004.05.002 (2004).
42. Gandhi, M., Brieva, J. C. & Lacouture, M. E. Dermatologic infections in cancer patients. Cancer treatment and research 161,
299–317, doi: 10.1007/978-3-319-04220-6_10 (2014).
43. Hagymasi, K. & Tulassay, Z. infection: New pathogenetic and clinical aspects. World journal of gastroenterology: WJG 20,
6386–6399, doi: 10.3748/wjg.v20.i21.6386 (2014).
44. Pierantozzi, M. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology
66, 1824–1829, doi: 10.1212/01.wnl.0000221672.01272.ba (2006).
45. Marin, M., Gudiol, C., Garcia-Vidal, C., Ardanuy, C. & Carratala, J. Bloodstream infections in patients with solid tumors:
epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine 93, 143–149, doi: 10.1097/
MD.0000000000000026 (2014).
46. Olsina, M. et al. [Isolation of Haemophilus spp. from samples of pleural fluid: 11 years’ review]. Enfermedades infecciosas y
microbiologia clinica 12, 235–240 (1994).
47. Han, X. H. et al. Clostridium difficile infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer
chemotherapy. Anaerobe 24, 82–84, doi: 10.1016/j.anaerobe.2013.05.004 (2013).
48. Skinner, E. C. et al. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer
and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin. The Journal of urology 190, 1200–1204,
doi: 10.1016/j.juro.2013.04.031 (2013).
49. Houghton, B. B. et al. Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic
review with meta-analysis. BJU international 111, 977–983, doi: 10.1111/j.1464-410X.2012.11390.x (2013).
50. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W. & Vogelstein, B. Combination bacteriolytic therapy for the treatment of
experimental tumors. Proceedings of the National Academy of Sciences of the United States of America 98, 15155–15160,
doi: 10.1073/pnas.251543698 (2001).
51. Jia, L. J. et al. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose
and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 121, 666–674, doi: 10.1002/ijc.22688 (2007).
52. Valle, A., Le Borgne, S., Bolivar, J., Cabrera, G. & Cantero, D. Study of the role played by NfsA, NfsB nitroreductase and NemA
flavin reductase from Escherichia coli in the conversion of ethyl 2-(2′-nitrophenoxy)acetate to 4-hydroxy-(2H)-1,4-benzoxazin3(4H)-one (D-DIBOA), a benzohydroxamic acid with interesting biological properties. Applied microbiology and biotechnology
94, 163–171, doi: 10.1007/s00253-011-3787-0 (2012).
53. Somers, K. D. et al. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of
flt3 ligand immunotherapy. Int J Cancer 107, 773–780, doi: 10.1002/ijc.11464 (2003).
54. Ahmad, S., Casey, G., Sweeney, P., Tangney, M. & O’Sullivan, G. C. Prostate stem cell antigen DNA vaccination breaks tolerance
to self-antigen and inhibits prostate cancer growth. Molecular therapy: the journal of the American Society of Gene Therapy 17,
1101–1108, doi: 10.1038/mt.2009.66 (2009).

Acknowledgments

We would like to thank Dr. Chwanrow K. Baban, Ms. Deirdre O’Hanlon, Dr. Bill Bennett and Ms. Marian
Manning (Cork University Hospital, Cork, Ireland) for facilitating patient sample collection and Dr. Sara
Collins for technical help with in vitro drug screening.

Author Contributions

P.L. designed and performed in vitro experiments and co-wrote the manuscript. J.C., M.S. and C.M.
performed in vivo experiments. F.O.M. led the HPLC studies. G.R. and C.U. contributed to patient tissue
bioinformatics work. W.L.B. contributed to the design of drug experiments. M.T. designed and led the
study and co-wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Lehouritis, P. et al. Local bacteria affect the efficacy of chemotherapeutic
drugs. Sci. Rep. 5, 14554; doi: 10.1038/srep14554 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The
images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from the license holder to reproduce
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Scientific Reports | 5:14554 | DOI: 10.1038/srep14554

12

